Molecular mechanisms and antisense oligonucleotide therapies of familial amyotrophic lateral sclerosis.
PMID 39176177 | PMCID PMC11338942 | DOI 10.1016/j.omtn.2024.102271 · Molecular therapy. Nucleic acids · 2024 · View on PubMed ↗
Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease, presents considerable challenges in both diagnosis and treatment. It is categorized into sporadic and familial amyotrophic lateral sclerosis (fALS); the latter accounts for approximately 10% of cases and is primarily inherited in an autosomal dominant manner. This review summarizes the molecular genetics of fALS, highlighting key mutations that contribute to its pathogenesis, such as mutations in SOD1, FUS, and C9orf72. Central to this discourse is exploring antisense oligonucleotides (ASOs) that target these genetic aberrations, providing a promising therapeutic strategy. This review provides a detailed overview of the molecular mechanisms underlying fALS and the potential therapeutic value of ASOs, offering new insights into treating neurodegenerative diseases.
Validated evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SOD1 | “This review summarizes the molecular genetics of fALS, highlighting key mutations that contribute to its pathogenesis, such as mutations in SOD1, FUS, and C9orf72.” | 0.98 | hgnc_dict_v1 |
| gene | FUS | “This review summarizes the molecular genetics of fALS, highlighting key mutations that contribute to its pathogenesis, such as mutations in SOD1, FUS, and C9orf72.” | 0.98 | hgnc_dict_v1 |
| gene | C9orf72 | “This review summarizes the molecular genetics of fALS, highlighting key mutations that contribute to its pathogenesis, such as mutations in SOD1, FUS, and C9orf72.” | 0.98 | hgnc_dict_v1 |
| phenotype | amyotrophic lateral sclerosis | “Molecular mechanisms and antisense oligonucleotide therapies of familial amyotrophic lateral sclerosis.” | 0.98 | phenotype_alias_lexicon_v2 |